vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1424Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВЛИЯНИЕ ИНФЛИКСИМАБА НА ДИНАМИКУ ФУНКЦИОНАЛЬНОГО КЛАССА И РЕНТГЕНОЛОГИЧЕСКИЕ ИЗМЕНЕНИЯ ХРЯЩЕВОЙ И КОСТНОЙ ТКАНИ СУСТАВОВ У БОЛЬНЫХ С РАЗЛИЧНЫМИ ВАРИАНТАМИ ЮВЕНИЛЬНОГО АРТРИТАEFFECT OF INFLIXIMAB ON DYNAMICS OF FUNCTIONAL CLASS AND RADIOLOGICAL SIGN OF BONE AND CARTILAGINOUS TISSUES ALTERATION OF JOINTS IN PATIENTS WITH DIFFERENT TYPES OF JUVENILE ARTHRITISАлексееваЕ.И.AlexeevaE.I.АлексееваА.М.AlekseevaA.M.ВалиеваС.И.ValievaS.I.БзароваТ.М.BzarovaT.M.ДенисоваР.В.DenisovaR.V.МихалеваГ.В.MikhalevaG.V.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowRussian FederationМосковская медицинская академия им. И.М. СеченоваРоссияI.M. Sechenov Moscow Medical AcademyRussian Federation20080511201574Вопросы современной педиатрии3044Copyright © Алексеева Е., Алексеева А., Валиева С., Бзарова Т., Денисова Р., Михалева Г., 20082008Алексеева Е., Алексеева А., Валиева С., Бзарова Т., Денисова Р., Михалева Г.Alexeeva E., Alekseeva A., Valieva S., Bzarova T., Denisova R., Mikhaleva G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1424ReferencesCush J. J. Rheumatoid arthritis. Clin. Symp. 1999; 51: 40.Cush J. J. Rheumatoid arthritis. Clin. Symp. 1999; 51: 40.Ройт А., Бростофф Дж., Мейл Д. Иммунология. 2000.Ройт А., Бростофф Дж., Мейл Д. Иммунология. 2000.Brenann F.M., Feldman M. Cytokines in autoimmunity. Curr. Opin. Immunol. 1992; 4: 754–759.Brenann F.M., Feldman M. Cytokines in autoimmunity. Curr. Opin. Immunol. 1992; 4: 754–759.Sewell E., Trentham D. Pathogenesis of rheumatoid arthritis. Lancet. 1993; 341: 283-286.Sewell E., Trentham D. Pathogenesis of rheumatoid arthritis. Lancet. 1993; 341: 283-286.Arend W.P., Dayer J.M. Inhibition of the production and effects of interleukin–1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 1995; 38: 151–160.Arend W.P., Dayer J.M. Inhibition of the production and effects of interleukin–1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 1995; 38: 151–160.Moore T.L. Immunopathogenes of juvenile rheumatoid arthritis. Curr. Opin. Rheumatol. 1999; 11: 377–383.Moore T.L. Immunopathogenes of juvenile rheumatoid arthritis. Curr. Opin. Rheumatol. 1999; 11: 377–383.Brahn E., Peacock D., Banquero M., Lui D. Effects of tumor necrosis alpha (TNF-α) on collagen arthritis. Lymphokine Cytotine Res. 1992; 11: 253–256.Brahn E., Peacock D., Banquero M., Lui D. Effects of tumor necrosis alpha (TNF-α) on collagen arthritis. Lymphokine Cytotine Res. 1992; 11: 253–256.Brennan F.M, Browne K.A., Green P.A., et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor (cA2) therapy. Br. J. Rheumatol. 1997; 36: 643–650.Brennan F.M, Browne K.A., Green P.A., et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor (cA2) therapy. Br. J. Rheumatol. 1997; 36: 643–650.Danks L., Sabokbar A., Gundle R., Athanasou N.A. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann. Rheum. Dis. 2002; 61: 916–921.Danks L., Sabokbar A., Gundle R., Athanasou N.A. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann. Rheum. Dis. 2002; 61: 916–921.Насонов Е.Л., Самсонов М.Ю., Тилз Г.П. и др., 1999; Насонов Е.Л., Самсонов М.Ю., Тилз Г.П. и др. Растворимые молекулы адгезии (Р–селектин, ICAM-3) при ревматоидном артрите. Терапевтический архив. 1999; 5: 17–20.Насонов Е.Л., Самсонов М.Ю., Тилз Г.П. и др., 1999; Насонов Е.Л., Самсонов М.Ю., Тилз Г.П. и др. Растворимые молекулы адгезии (Р–селектин, ICAM-3) при ревматоидном артрите. Терапевтический архив. 1999; 5: 17–20.Moser R.B., Schleiffenbaum B., Groscurth P., Fehr J. Interleikin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J. Clinic. Invest. 1989; 83: 444–455.Moser R.B., Schleiffenbaum B., Groscurth P., Fehr J. Interleikin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J. Clinic. Invest. 1989; 83: 444–455.Mannel D.N., Echtenacher B. TNF in the inflammatory response. Chem. Immunol. 2000; 74: 141–161.Mannel D.N., Echtenacher B. TNF in the inflammatory response. Chem. Immunol. 2000; 74: 141–161.Tak P.P., Taylor P.C., Breedveld F.C. et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39: 1077–1081.Tak P.P., Taylor P.C., Breedveld F.C. et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39: 1077–1081.Den Broeder A.A., Joosten L.A., Saxnee T. et al. Long term anti-tumor necrosis factor alpha monotherapy in rheumatoid in rheumatoid arthritis: effects on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. 2002; 61: 311–318.Den Broeder A.A., Joosten L.A., Saxnee T. et al. Long term anti-tumor necrosis factor alpha monotherapy in rheumatoid in rheumatoid arthritis: effects on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. 2002; 61: 311–318.Shingu M., Nagai Y., Isayama T. et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin. Exp. Immunol. 1993; 94: 145–149.Shingu M., Nagai Y., Isayama T. et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin. Exp. Immunol. 1993; 94: 145–149.Black R.A., Rauch C.T., Kozlosky C.J. et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature. 1997; 385: 729–733.Black R.A., Rauch C.T., Kozlosky C.J. et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature. 1997; 385: 729–733.Barksby H.E., Milner J.M., Patterson A.M. et al. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degration in arthritis. Arthritis Rheum. 2006; 54: 3244–3253.Barksby H.E., Milner J.M., Patterson A.M. et al. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degration in arthritis. Arthritis Rheum. 2006; 54: 3244–3253.Georgopoulos S., Plows D., Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 1996; 46: 86–97.Georgopoulos S., Plows D., Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 1996; 46: 86–97.Williams R.O., Malfait A.M., Butler D.M. et al. Combination therapy with DMARDs and biological agents in collagen-induced arthritis. Clin. Exp. Rheumatol. 1999; 17: 115–120.Williams R.O., Malfait A.M., Butler D.M. et al. Combination therapy with DMARDs and biological agents in collagen-induced arthritis. Clin. Exp. Rheumatol. 1999; 17: 115–120.Williams R.O. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol. Biol. 2006; 361: 265–284.Williams R.O. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol. Biol. 2006; 361: 265–284.Maini R., St. Clair E.W., Breedveld F. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999; 4: 1932–1939.Maini R., St. Clair E.W., Breedveld F. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999; 4: 1932–1939.Lipsky P.E., van der Heijde D.M.F.M, St Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594–1602.Lipsky P.E., van der Heijde D.M.F.M, St Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594–1602.Bredveld F.C., Emery P., Keystone E. et al. Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. 2004; 63: 149–155.Bredveld F.C., Emery P., Keystone E. et al. Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. 2004; 63: 149–155.Vis M., Wolbink J., Soesbergen R. et al. Early changes in bone metabolism in patients with rheumatoid arthritis treated with infliximab. Ann. Rheum. Dis. 2002; 61: 51.Vis M., Wolbink J., Soesbergen R. et al. Early changes in bone metabolism in patients with rheumatoid arthritis treated with infliximab. Ann. Rheum. Dis. 2002; 61: 51.Алексеева Е.И., Алексеева А.М., Валиева С.И., Бзарова Т.М. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (2): 20–30.Алексеева Е.И., Алексеева А.М., Валиева С.И., Бзарова Т.М. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (2): 20–30.Алексеева Е.И., Алексеева А.М., Валиева С.И., Бзарова Т.М., Денисова Р.В. Влияние инфликсимаба на клинические и лабораторные показатели активности различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7 (2): 42–53.Алексеева Е.И., Алексеева А.М., Валиева С.И., Бзарова Т.М., Денисова Р.В. Влияние инфликсимаба на клинические и лабораторные показатели активности различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7 (2): 42–53.Долгополова А., Бисярина В., Алексеев А. Вопросы ревматологии. 1979; 4: 3–7.Долгополова А., Бисярина В., Алексеев А. Вопросы ревматологии. 1979; 4: 3–7.Arnet F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthr. Rheum. 1988; 27: 315–324.Arnet F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthr. Rheum. 1988; 27: 315–324.Steinbroker Q., Traeger C.H., Batterman R.C. Therapeutic criteria in rheumatoid arthritis. J. Am. Med. Assoc. 1949; 140: 659–662.Steinbroker Q., Traeger C.H., Batterman R.C. Therapeutic criteria in rheumatoid arthritis. J. Am. Med. Assoc. 1949; 140: 659–662.Sharp J.T., Young D.Y., Bluhm G.B. et al. How many joints in the hands and wrists should be included in a score of the radiological abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985; 28: 1326–1335.Sharp J.T., Young D.Y., Bluhm G.B. et al. How many joints in the hands and wrists should be included in a score of the radiological abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985; 28: 1326–1335.van der Heijde D.M.F.M., van´t Hof M.A., Reil P.L.C.M. et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of disease activity score. Ann. Rheum. Dis. 1990; 49: 916-920.van der Heijde D.M.F.M., van´t Hof M.A., Reil P.L.C.M. et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of disease activity score. Ann. Rheum. Dis. 1990; 49: 916-920.
The authors declare that there are no conflicts of interest present.